Skip to main content
Top
Published in: Diabetologia 9/2004

01-09-2004 | For Debate

Vascular calcification and osteolysis in diabetic neuropathy—is RANK-L the missing link?

Author: W. Jeffcoate

Published in: Diabetologia | Issue 9/2004

Login to get access

Abstract

Diabetic neuropathy is associated with osteopenia and calcification of vascular smooth muscle cells. These changes are most marked in patients with acute neuropathic osteoarthropathy (Charcot foot), in which osteopenia is universal and the prevalence of vascular calcification exceeds 90%. While it has been thought that both osteopenia and vascular calcification may be linked to sympathetic denervation with increased peripheral limb perfusion, the cellular mechanism was not clear. However, the recent recognition that the receptor activator of nuclear factor kappa B ligand (RANK-L)/osteoprotegerin (OPG) signalling pathway is central to the processes regulating bone turnover in a wide variety of medical conditions has raised the possibility that the same cytokines may be involved in the osteolysis which accompanies diabetic neuropathy. This is made more likely by the realisation that the RANK-L/OPG pathway is also thought to mediate the calcification of vascular smooth muscle cells in coronary and peripheral vascular disease. The circumstantial evidence underpinning this hypothesis is reviewed here, and it is suggested that the unregulated activation of RANK-L-mediated effects on bone and arteries may be triggered by the loss of nerve-derived peptides, e.g. calcitonin gene-related peptide, which normally exert a moderating influence on the pathway.
Literature
1.
go back to reference Edmonds ME, Morrison N, Laws JW, Watkins PJ (1982) Medial arterial calcification and diabetic neuropathy. BMJ 284:928–930PubMed Edmonds ME, Morrison N, Laws JW, Watkins PJ (1982) Medial arterial calcification and diabetic neuropathy. BMJ 284:928–930PubMed
2.
go back to reference Goebel FD, Fuessl HS (1983) Monckeberg’s sclerosis after sympathetic denervation in diabetic and non-diabetic subjects. Diabetologia 24:347–350PubMed Goebel FD, Fuessl HS (1983) Monckeberg’s sclerosis after sympathetic denervation in diabetic and non-diabetic subjects. Diabetologia 24:347–350PubMed
3.
go back to reference Corbin DO, Young RJ, Morrison DC et al. (1987) Blood flow in the foot, polyneuropathy and foot ulceration in diabetes mellitus. Diabetologia 30:468–473PubMed Corbin DO, Young RJ, Morrison DC et al. (1987) Blood flow in the foot, polyneuropathy and foot ulceration in diabetes mellitus. Diabetologia 30:468–473PubMed
4.
go back to reference Mayfield JA, Caps MT, Boyko EJ, Ahroni JH, Smith DG (2002) Relationship of medial arterial calcinosis to autonomic neuropathy and adverse outcomes in a diabetic veteran population. J Diabet Complications 16:165–171CrossRef Mayfield JA, Caps MT, Boyko EJ, Ahroni JH, Smith DG (2002) Relationship of medial arterial calcinosis to autonomic neuropathy and adverse outcomes in a diabetic veteran population. J Diabet Complications 16:165–171CrossRef
5.
go back to reference Chen NX, Moe SM (2003) Arterial calcification in diabetes. Curr Diab Rep 3:28–32PubMed Chen NX, Moe SM (2003) Arterial calcification in diabetes. Curr Diab Rep 3:28–32PubMed
6.
go back to reference Mozes G, Keresztury G, Kadar A et al. (1998) Atherosclerosis in amputated legs of patients with and without diabetes mellitus. Int Angiol 17:282–286PubMed Mozes G, Keresztury G, Kadar A et al. (1998) Atherosclerosis in amputated legs of patients with and without diabetes mellitus. Int Angiol 17:282–286PubMed
7.
go back to reference Carrington AL, Abbott CA, Griffiths J et al. (2001) Peripheral vascular and nerve function associated with lower limb amputation in people with and without diabetes. Clin Sci 101:261–266 Carrington AL, Abbott CA, Griffiths J et al. (2001) Peripheral vascular and nerve function associated with lower limb amputation in people with and without diabetes. Clin Sci 101:261–266
8.
go back to reference Sinha S, Munichoodappa C, Kozak GP (1972) Neuro-arthropathy (Charcot joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 51:191–210 Sinha S, Munichoodappa C, Kozak GP (1972) Neuro-arthropathy (Charcot joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 51:191–210
9.
go back to reference Clouse ME, Gramm HF, Legg M, Flood T (1974) Diabetic osteoarthropathy: clinical and roentgenographic observations in 90 cases. Am J Roentgenol 121:22–34 Clouse ME, Gramm HF, Legg M, Flood T (1974) Diabetic osteoarthropathy: clinical and roentgenographic observations in 90 cases. Am J Roentgenol 121:22–34
10.
go back to reference Ziegler R (1992) Diabetes mellitus and bone metabolism. Horm Metab Res Suppl 26:90–94PubMed Ziegler R (1992) Diabetes mellitus and bone metabolism. Horm Metab Res Suppl 26:90–94PubMed
11.
go back to reference Cundy T, Edmonds ME, Watkins PJ (1985) Osteopaenia and metatarsal fractures in diabetic neuropathy. Diabet Med 2:461–464PubMed Cundy T, Edmonds ME, Watkins PJ (1985) Osteopaenia and metatarsal fractures in diabetic neuropathy. Diabet Med 2:461–464PubMed
12.
go back to reference Kayath MJ, Dib SA, Vieia JG (1994) Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabet Complications 8:97–104CrossRef Kayath MJ, Dib SA, Vieia JG (1994) Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabet Complications 8:97–104CrossRef
13.
go back to reference Forst T, Pfutzner A, Kann P et al. (1995) Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 12:874–879PubMed Forst T, Pfutzner A, Kann P et al. (1995) Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 12:874–879PubMed
14.
go back to reference Rix M, Andreassen H, Eskildsen P (1999) Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 22:827–831PubMed Rix M, Andreassen H, Eskildsen P (1999) Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 22:827–831PubMed
15.
go back to reference Edmonds ME, Clarke MB, Newton S, Barrett J, Watkins PJ (1985) Increased uptake of bone radiopharmaceutical in diabetic neuropathy. Q J Med 57:843–855PubMed Edmonds ME, Clarke MB, Newton S, Barrett J, Watkins PJ (1985) Increased uptake of bone radiopharmaceutical in diabetic neuropathy. Q J Med 57:843–855PubMed
16.
go back to reference Jeffcoate W, Lima J, Nobrega L (2000) The Charcot foot. Diabet Med 17:1–6CrossRef Jeffcoate W, Lima J, Nobrega L (2000) The Charcot foot. Diabet Med 17:1–6CrossRef
17.
go back to reference Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S (2002) Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45:1085–1096CrossRefPubMed Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S (2002) Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45:1085–1096CrossRefPubMed
18.
go back to reference Hofbauer LC, Heufelder AE (2000) The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355–2363CrossRefPubMed Hofbauer LC, Heufelder AE (2000) The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85:2355–2363CrossRefPubMed
20.
go back to reference Schoppet M, Preissner KT, Hofbauer LC (2002) RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22:549–553CrossRefPubMed Schoppet M, Preissner KT, Hofbauer LC (2002) RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22:549–553CrossRefPubMed
21.
go back to reference Ashcroft AJ, Davies FE, Morgan GJ (2003) Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 4:284–292CrossRefPubMed Ashcroft AJ, Davies FE, Morgan GJ (2003) Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 4:284–292CrossRefPubMed
22.
go back to reference Mancini L, Moradi-Bidhendi N, Brandi ML, Perretti M, MacIntyre I (2000) Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. Biochem Biophys Res Comm 279:391–397 Mancini L, Moradi-Bidhendi N, Brandi ML, Perretti M, MacIntyre I (2000) Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. Biochem Biophys Res Comm 279:391–397
23.
go back to reference Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR (2001) Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29:162–168CrossRefPubMed Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR (2001) Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29:162–168CrossRefPubMed
24.
go back to reference Imai S, Matsusue Y (2002) Neuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P-, and tyrosine hydroxylase-containing nerves and the bone. Microsc Res Tech 58:61–69CrossRefPubMed Imai S, Matsusue Y (2002) Neuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P-, and tyrosine hydroxylase-containing nerves and the bone. Microsc Res Tech 58:61–69CrossRefPubMed
25.
go back to reference Hofbauer LC, Schoppet M (2001) Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 358:257–259CrossRefPubMed Hofbauer LC, Schoppet M (2001) Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 358:257–259CrossRefPubMed
26.
go back to reference Buckley KA, Fraser WD (2002) Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. Ann Clin Biochem 39:551–556CrossRefPubMed Buckley KA, Fraser WD (2002) Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. Ann Clin Biochem 39:551–556CrossRefPubMed
27.
go back to reference Schoppet M, Sattler ANM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88:1024–1028CrossRefPubMed Schoppet M, Sattler ANM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88:1024–1028CrossRefPubMed
28.
go back to reference Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631–637CrossRefPubMed Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631–637CrossRefPubMed
29.
go back to reference Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM (2003) Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 149:39–42PubMed Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM (2003) Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 149:39–42PubMed
30.
go back to reference Demer LL, Tintut Y, Parhami F (2002) Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens 11:437–443CrossRefPubMed Demer LL, Tintut Y, Parhami F (2002) Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens 11:437–443CrossRefPubMed
31.
go back to reference Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K (2003) Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J Cell Physiol 196:180–189CrossRefPubMed Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K (2003) Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J Cell Physiol 196:180–189CrossRefPubMed
32.
go back to reference Nitta K, Akiba T, Uchida K et al. (2003) The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42:303–309CrossRefPubMed Nitta K, Akiba T, Uchida K et al. (2003) The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42:303–309CrossRefPubMed
33.
go back to reference Sasaki T (2003) Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. Microsc Res Tech 61:483–495CrossRefPubMed Sasaki T (2003) Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. Microsc Res Tech 61:483–495CrossRefPubMed
34.
go back to reference Kon T, Cho TJ, Aizawa T et al. (2001) Expression of osteoprotegerin, receptor activator of NF-kappa ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 16:1004–1014PubMed Kon T, Cho TJ, Aizawa T et al. (2001) Expression of osteoprotegerin, receptor activator of NF-kappa ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 16:1004–1014PubMed
35.
go back to reference Knaggs RI (1926) Charcot joints. In: Knaggs RI (ed.) Inflammatory and toxic disorders of bone. John Wright, Bristol, pp 105–119 Knaggs RI (1926) Charcot joints. In: Knaggs RI (ed.) Inflammatory and toxic disorders of bone. John Wright, Bristol, pp 105–119
36.
go back to reference Edelman SV, Kosofsky EM, Paul RA, Kozak GP (1987) Neuro-arthropathy (Charcot’s joint) in diabetes mellitus following revascularisation surgery. Arch Intern Med 147:1504–1508CrossRefPubMed Edelman SV, Kosofsky EM, Paul RA, Kozak GP (1987) Neuro-arthropathy (Charcot’s joint) in diabetes mellitus following revascularisation surgery. Arch Intern Med 147:1504–1508CrossRefPubMed
37.
go back to reference Selby PL, Young MJ, Bouton AJM (1994) Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med 11:28–31 Selby PL, Young MJ, Bouton AJM (1994) Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med 11:28–31
38.
go back to reference Jude EB, Selby PL, Burgess J et al. (2001) Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44:2032–2037CrossRefPubMed Jude EB, Selby PL, Burgess J et al. (2001) Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44:2032–2037CrossRefPubMed
39.
go back to reference Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 51:65–74 Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 51:65–74
40.
go back to reference Rogers MJ (2003) New insights into the mechanism of action of bisphosphonates. Curr Pharm Des 9:2643–2658PubMed Rogers MJ (2003) New insights into the mechanism of action of bisphosphonates. Curr Pharm Des 9:2643–2658PubMed
41.
go back to reference Maillefert JF, Chatard C, Owen S, Peere T, Taverner C, Tebib J (1995) Treatment of refractory reflex sympathetic dystrophy with pamidronate. Ann Rheum Dis 54:687 Maillefert JF, Chatard C, Owen S, Peere T, Taverner C, Tebib J (1995) Treatment of refractory reflex sympathetic dystrophy with pamidronate. Ann Rheum Dis 54:687
42.
go back to reference Cortet B, Flipo R-M, Coquerelle P, Duquesnoy B, Delcambre B (1997) Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of the efficacy and safety of second generation bisphosphonate pamidronate. Clin Rheumatol 16:51–56PubMed Cortet B, Flipo R-M, Coquerelle P, Duquesnoy B, Delcambre B (1997) Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of the efficacy and safety of second generation bisphosphonate pamidronate. Clin Rheumatol 16:51–56PubMed
43.
go back to reference Kudo O, Sabokbar A, Pocock A, Itonaga I, Athanason NA (2002) Isolation of human osteoclasts formed in vitro: hormonal effects on bone-resorbing activity of human osteoclasts. Calcif Tissue Int 71:539–546CrossRefPubMed Kudo O, Sabokbar A, Pocock A, Itonaga I, Athanason NA (2002) Isolation of human osteoclasts formed in vitro: hormonal effects on bone-resorbing activity of human osteoclasts. Calcif Tissue Int 71:539–546CrossRefPubMed
44.
go back to reference Price PA, Caputo JM, Williamson MK (2002) Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodelling compartment. J Bone Miner Res 17:1171–1179PubMed Price PA, Caputo JM, Williamson MK (2002) Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodelling compartment. J Bone Miner Res 17:1171–1179PubMed
45.
go back to reference Forsblom CM, Sane T, Group PH et al. (1998) Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 41:1253–1262CrossRefPubMed Forsblom CM, Sane T, Group PH et al. (1998) Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 41:1253–1262CrossRefPubMed
46.
go back to reference Maser RE, Mitchell BD, Vinik AI, Freeman R (2003) The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes. Diabetes Care 26:1895–1901PubMed Maser RE, Mitchell BD, Vinik AI, Freeman R (2003) The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes. Diabetes Care 26:1895–1901PubMed
47.
go back to reference Klassen PS, Lowrie EG, Reddan DN et al. (2002) Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287:1548–1555CrossRefPubMed Klassen PS, Lowrie EG, Reddan DN et al. (2002) Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287:1548–1555CrossRefPubMed
48.
go back to reference Tozawa M, Iseki K, Iseki C et al. (2002) Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 61:717–726CrossRefPubMed Tozawa M, Iseki K, Iseki C et al. (2002) Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 61:717–726CrossRefPubMed
Metadata
Title
Vascular calcification and osteolysis in diabetic neuropathy—is RANK-L the missing link?
Author
W. Jeffcoate
Publication date
01-09-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1477-5

Other articles of this Issue 9/2004

Diabetologia 9/2004 Go to the issue